Leonid Timashev
Stock Analyst at RBC Capital
(4.24)
# 482
Out of 5,048 analysts
117
Total ratings
56.31%
Success rate
13.78%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Outperform | $189 → $198 | $132.30 | +49.66% | 14 | Nov 4, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $77 | $59.25 | +29.97% | 1 | Nov 3, 2025 | |
| INSM Insmed | Maintains: Outperform | $139 → $215 | $185.69 | +15.78% | 6 | Oct 31, 2025 | |
| BCYC Bicycle Therapeutics | Downgrades: Sector Perform | $27 → $11 | $7.11 | +54.71% | 2 | Oct 31, 2025 | |
| XNCR Xencor | Maintains: Outperform | $15 → $18 | $14.32 | +25.70% | 2 | Oct 27, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $45 → $47 | $30.53 | +53.95% | 5 | Oct 23, 2025 | |
| EXEL Exelixis | Reiterates: Sector Perform | $45 | $38.21 | +17.77% | 2 | Oct 21, 2025 | |
| CRMD CorMedix | Maintains: Outperform | $21 → $22 | $11.48 | +91.64% | 2 | Oct 21, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $38 → $41 | $30.43 | +34.74% | 3 | Oct 21, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $145 → $151 | $138.09 | +9.35% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $77 | $32.62 | +136.05% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $8.05 | +61.49% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $4.79 | +46.14% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $49 | $17.34 | +182.58% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $39 | $37.38 | +4.33% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $349 → $364 | $315.21 | +15.48% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $53 | $40.80 | +29.90% | 1 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $4.12 | +21.51% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $2.47 | +549.09% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $54 → $21 | $14.09 | +49.04% | 12 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $80 | $59.78 | +33.82% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.96 | +102.02% | 6 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.47 | +104.78% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $103.09 | -32.10% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $6.41 | +180.81% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $6.52 | -38.66% | 8 | Aug 6, 2024 |
Axsome Therapeutics
Nov 4, 2025
Maintains: Outperform
Price Target: $189 → $198
Current: $132.30
Upside: +49.66%
Revolution Medicines
Nov 3, 2025
Initiates: Outperform
Price Target: $77
Current: $59.25
Upside: +29.97%
Insmed
Oct 31, 2025
Maintains: Outperform
Price Target: $139 → $215
Current: $185.69
Upside: +15.78%
Bicycle Therapeutics
Oct 31, 2025
Downgrades: Sector Perform
Price Target: $27 → $11
Current: $7.11
Upside: +54.71%
Xencor
Oct 27, 2025
Maintains: Outperform
Price Target: $15 → $18
Current: $14.32
Upside: +25.70%
Alkermes
Oct 23, 2025
Maintains: Outperform
Price Target: $45 → $47
Current: $30.53
Upside: +53.95%
Exelixis
Oct 21, 2025
Reiterates: Sector Perform
Price Target: $45
Current: $38.21
Upside: +17.77%
CorMedix
Oct 21, 2025
Maintains: Outperform
Price Target: $21 → $22
Current: $11.48
Upside: +91.64%
IDEAYA Biosciences
Oct 21, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $30.43
Upside: +34.74%
Jazz Pharmaceuticals
Aug 28, 2025
Maintains: Outperform
Price Target: $145 → $151
Current: $138.09
Upside: +9.35%
Aug 12, 2025
Maintains: Outperform
Price Target: $75 → $77
Current: $32.62
Upside: +136.05%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $8.05
Upside: +61.49%
Aug 8, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $4.79
Upside: +46.14%
Aug 8, 2025
Maintains: Outperform
Price Target: $48 → $49
Current: $17.34
Upside: +182.58%
Aug 7, 2025
Maintains: Outperform
Price Target: $38 → $39
Current: $37.38
Upside: +4.33%
Aug 7, 2025
Maintains: Outperform
Price Target: $349 → $364
Current: $315.21
Upside: +15.48%
Jul 16, 2025
Maintains: Outperform
Price Target: $68 → $53
Current: $40.80
Upside: +29.90%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $4.12
Upside: +21.51%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $2.47
Upside: +549.09%
May 19, 2025
Downgrades: Sector Perform
Price Target: $54 → $21
Current: $14.09
Upside: +49.04%
May 7, 2025
Maintains: Outperform
Price Target: $82 → $80
Current: $59.78
Upside: +33.82%
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.96
Upside: +102.02%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.47
Upside: +104.78%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $103.09
Upside: -32.10%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $6.41
Upside: +180.81%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $6.52
Upside: -38.66%